Cerenome Statistics
Total Valuation
Cerenome has a market cap or net worth of $15.10 million. The enterprise value is $6.56 million.
| Market Cap | 15.10M |
| Enterprise Value | 6.56M |
Important Dates
The next estimated earnings date is Thursday, October 29, 2026, after market close.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cerenome has 7.59 million shares outstanding. The number of shares has increased by 830.64% in one year.
| Current Share Class | 7.59M |
| Shares Outstanding | 7.59M |
| Shares Change (YoY) | +830.64% |
| Shares Change (QoQ) | +3.80% |
| Owned by Insiders (%) | 0.87% |
| Owned by Institutions (%) | 14.42% |
| Float | 7.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.59 |
| Forward PS | 0.99 |
| PB Ratio | 2.66 |
| P/TBV Ratio | 3.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.56 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.37, with a Debt / Equity ratio of 0.01.
| Current Ratio | 1.37 |
| Quick Ratio | 1.23 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,200.00 |
Financial Efficiency
Return on equity (ROE) is -614.05% and return on invested capital (ROIC) is -385.02%.
| Return on Equity (ROE) | -614.05% |
| Return on Assets (ROA) | -135.36% |
| Return on Invested Capital (ROIC) | -385.02% |
| Return on Capital Employed (ROCE) | -483.25% |
| Weighted Average Cost of Capital (WACC) | 11.95% |
| Revenue Per Employee | $150,107 |
| Profits Per Employee | -$931,714 |
| Employee Count | 28 |
| Asset Turnover | 0.34 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -80.31% in the last 52 weeks. The beta is 1.39, so Cerenome's price volatility has been higher than the market average.
| Beta (5Y) | 1.39 |
| 52-Week Price Change | -80.31% |
| 50-Day Moving Average | 3.09 |
| 200-Day Moving Average | 6.20 |
| Relative Strength Index (RSI) | 30.85 |
| Average Volume (20 Days) | 88,937 |
Short Selling Information
The latest short interest is 651,888, so 8.59% of the outstanding shares have been sold short.
| Short Interest | 651,888 |
| Short Previous Month | 649,181 |
| Short % of Shares Out | 8.59% |
| Short % of Float | 8.66% |
| Short Ratio (days to cover) | 8.21 |
Income Statement
In the last 12 months, Cerenome had revenue of $4.20 million and -$26.09 million in losses. Loss per share was -$4.37.
| Revenue | 4.20M |
| Gross Profit | -8.30M |
| Operating Income | -26.40M |
| Pretax Income | -26.09M |
| Net Income | -26.09M |
| EBITDA | -25.95M |
| EBIT | -26.40M |
| Loss Per Share | -$4.37 |
Balance Sheet
The company has $8.59 million in cash and $44,000 in debt, with a net cash position of $8.54 million or $1.13 per share.
| Cash & Cash Equivalents | 8.59M |
| Total Debt | 44,000 |
| Net Cash | 8.54M |
| Net Cash Per Share | $1.13 |
| Equity (Book Value) | 5.46M |
| Book Value Per Share | 0.75 |
| Working Capital | 3.20M |
Cash Flow
In the last 12 months, operating cash flow was -$22.18 million and capital expenditures -$1.37 million, giving a free cash flow of -$23.55 million.
| Operating Cash Flow | -22.18M |
| Capital Expenditures | -1.37M |
| Depreciation & Amortization | 455,000 |
| Net Borrowing | -22,000 |
| Free Cash Flow | -23.55M |
| FCF Per Share | -$3.10 |
Margins
| Gross Margin | -197.57% |
| Operating Margin | -628.12% |
| Pretax Margin | -620.70% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cerenome does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -830.64% |
| Shareholder Yield | -830.64% |
| Earnings Yield | -172.73% |
| FCF Yield | -155.92% |
Analyst Forecast
The average price target for Cerenome is $32.50, which is 1,533.17% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $32.50 |
| Price Target Difference | 1,533.17% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 105.61% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 2, 2026. It was a reverse split with a ratio of 1:25.
| Last Split Date | Apr 2, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
Cerenome has an Altman Z-Score of -55.16 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -55.16 |
| Piotroski F-Score | 2 |